miR-429 Suppresses Endometrial Cancer Progression and Drug Resistance via DDX53
Abstract
:1. Introduction
2. Materials and Methods
2.1. Cells and Reagents
2.2. Transfections
2.3. Quantitative Real-Time PCR (qRT-PCR)
2.4. Western Blotting (WB)
2.5. Luciferase Reporter Assays
2.6. Cell Viability
2.7. Drug Treatment Assays
2.8. Scratch Wound Healing Assays
2.9. Invasion Assays
2.10. Colony Formation Assays
2.11. In Vivo Studies
2.12. Statistics
3. Results
3.1. DDX53 Positively Correlates with EC Progression and Metastasis
3.2. DDX53 Upregulates Chemoresistance and Mesenchymal Markers in EC Cells
3.3. MiR-429 Regulates EC Metastasis and Proliferation by Targeting DDX53
3.4. Downregulated miR-429 Contributes to EMT and Increased Anti-Cancer Sensitivity in EC Cells
3.5. The miR-429/DDX53 Axis Regulates In Vivo EC Tumor Progression
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Linder, P.; Jankowsky, E. From unwinding to clamping—The DEAD box RNA helicase family. Nat. Rev. Mol. Cell Biol. 2011, 12, 505–516. [Google Scholar] [CrossRef] [PubMed]
- Mo, J.; Liang, H.; Su, C.; Li, P.; Chen, J.; Zhang, B. DDX3X: Structure, physiologic functions and cancer. Mol. Cancer 2021, 20, 38. [Google Scholar] [CrossRef] [PubMed]
- Zhang, L.; Li, X. DEAD-Box RNA Helicases in Cell Cycle Control and Clinical Therapy. Cells 2021, 10, 1540. [Google Scholar] [CrossRef]
- Cho, B.; Lim, Y.; Lee, D.Y.; Park, S.Y.; Lee, H.; Kim, W.H.; Yang, H.; Bang, Y.J.; Jeoung, D.I. Identification and characterization of a novel cancer/testis antigen gene CAGE. Biochem. Biophys. Res. Commun. 2002, 292, 715–726. [Google Scholar] [CrossRef]
- Iwata, T.; Fujita, T.; Hirao, N.; Matsuzaki, Y.; Okada, T.; Mochimaru, H.; Susumu, N.; Matsumoto, E.; Sugano, K.; Yamashita, N.; et al. Frequent immune responses to a cancer/testis antigen, CAGE, in patients with microsatellite instability-positive endometrial cancer. Clin. Cancer Res. 2005, 11, 3949–3957. [Google Scholar] [CrossRef] [PubMed]
- Liggins, A.P.; Lim, S.H.; Soilleux, E.J.; Pulford, K.; Banham, A.H. A panel of cancer-testis genes exhibiting broad-spectrum expression in haematological malignancies. Cancer Immun. 2010, 10, 8. [Google Scholar] [PubMed]
- Saliminejad, K.; Khorram Khorshid, H.R.; Soleymani Fard, S.; Ghaffari, S.H. An overview of microRNAs: Biology, functions, therapeutics, and analysis methods. J. Cell. Physiol. 2019, 234, 5451–5465. [Google Scholar] [CrossRef]
- Cai, H.; An, Y.; Chen, X.; Sun, D.; Chen, T.; Peng, Y.; Zhu, F.; Jiang, Y.; He, X. Epigenetic inhibition of miR-663b by long non-coding RNA HOTAIR promotes pancreatic cancer cell proliferation via up-regulation of insulin-like growth factor 2. Oncotarget 2016, 7, 86857–86870. [Google Scholar] [CrossRef]
- Jeong, J.Y.; Kang, H.; Kim, T.H.; Kim, G.; Heo, J.H.; Kwon, A.Y.; Kim, S.; Jung, S.G.; An, H.J. MicroRNA-136 inhibits cancer stem cell activity and enhances the anti-tumor effect of paclitaxel against chemoresistant ovarian cancer cells by targeting Notch3. Cancer Lett. 2017, 386, 168–178. [Google Scholar] [CrossRef]
- Su, D.N.; Wu, S.P.; Chen, H.T.; He, J.H. HOTAIR, a long non-coding RNA driver of malignancy whose expression is activated by FOXC1, negatively regulates miRNA-1 in hepatocellular carcinoma. Oncol. Lett. 2016, 12, 4061–4067. [Google Scholar] [CrossRef]
- Wang, P.; Deng, Y.; Fu, X. MiR-509-5p suppresses the proliferation, migration, and invasion of non-small cell lung cancer by targeting YWHAG. Biochem. Biophys. Res. Commun. 2017, 482, 935–941. [Google Scholar] [CrossRef]
- Valeri, N.; Gasparini, P.; Fabbri, M.; Braconi, C.; Veronese, A.; Lovat, F.; Adair, B.; Vannini, I.; Fanini, F.; Bottoni, A.; et al. Modulation of mismatch repair and genomic stability by miR-155. Proc. Natl. Acad. Sci. USA 2010, 107, 6982–6987. [Google Scholar] [CrossRef] [PubMed]
- Vosa, U.; Vooder, T.; Kolde, R.; Fischer, K.; Valk, K.; Tonisson, N.; Roosipuu, R.; Vilo, J.; Metspalu, A.; Annilo, T. Identification of miR-374a as a prognostic marker for survival in patients with early-stage nonsmall cell lung cancer. Genes Chromosomes Cancer 2011, 50, 812–822. [Google Scholar] [CrossRef] [PubMed]
- Kumarswamy, R.; Mudduluru, G.; Ceppi, P.; Muppala, S.; Kozlowski, M.; Niklinski, J.; Papotti, M.; Allgayer, H. MicroRNA-30a inhibits epithelial-to-mesenchymal transition by targeting Snai1 and is downregulated in non-small cell lung cancer. Int. J. Cancer 2012, 130, 2044–2053. [Google Scholar] [CrossRef] [PubMed]
- Klicka, K.; Grzywa, T.M.; Mielniczuk, A.; Klinke, A.; Wlodarski, P.K. The role of miR-200 family in the regulation of hallmarks of cancer. Front. Oncol. 2022, 12, 965231. [Google Scholar] [CrossRef] [PubMed]
- Dong, S.J.; Cai, X.J.; Li, S.J. The Clinical Significance of MiR-429 as a Predictive Biomarker in Colorectal Cancer Patients Receiving 5-Fluorouracil Treatment. Med. Sci. Monit. 2016, 22, 3352–3361. [Google Scholar] [CrossRef]
- Chen, H.; Xia, B.; Liu, T.; Lin, M.; Lou, G. KIAA0101, a target gene of miR-429, enhances migration and chemoresistance of epithelial ovarian cancer cells. Cancer Cell Int. 2016, 16, 74. [Google Scholar] [CrossRef]
- Goeppert, B.; Ernst, C.; Baer, C.; Roessler, S.; Renner, M.; Mehrabi, A.; Hafezi, M.; Pathil, A.; Warth, A.; Stenzinger, A.; et al. Cadherin-6 is a putative tumor suppressor and target of epigenetically dysregulated miR-429 in cholangiocarcinoma. Epigenetics 2016, 11, 780–790. [Google Scholar] [CrossRef]
- Machackova, T.; Mlcochova, H.; Stanik, M.; Dolezel, J.; Fedorko, M.; Pacik, D.; Poprach, A.; Svoboda, M.; Slaby, O. MiR-429 is linked to metastasis and poor prognosis in renal cell carcinoma by affecting epithelial-mesenchymal transition. Tumour. Biol. 2016, 37, 14653–14658. [Google Scholar] [CrossRef]
- Li, J.; Du, L.; Yang, Y.; Wang, C.; Liu, H.; Wang, L.; Zhang, X.; Li, W.; Zheng, G.; Dong, Z. MiR-429 is an independent prognostic factor in colorectal cancer and exerts its anti-apoptotic function by targeting SOX2. Cancer Lett. 2013, 329, 84–90. [Google Scholar] [CrossRef]
- Sun, Y.; Shen, S.; Liu, X.; Tang, H.; Wang, Z.; Yu, Z.; Li, X.; Wu, M. MiR-429 inhibits cells growth and invasion and regulates EMT-related marker genes by targeting Onecut2 in colorectal carcinoma. Mol. Cell. Biochem. 2014, 390, 19–30. [Google Scholar] [CrossRef] [PubMed]
- Lei, W.; Liu, Y.E.; Zheng, Y.; Qu, L. MiR-429 inhibits oral squamous cell carcinoma growth by targeting ZEB1. Med. Sci. Monit. 2015, 21, 383–389. [Google Scholar] [CrossRef]
- Ye, Z.B.; Ma, G.; Zhao, Y.H.; Xiao, Y.; Zhan, Y.; Jing, C.; Gao, K.; Liu, Z.H.; Yu, S.J. miR-429 inhibits migration and invasion of breast cancer cells in vitro. Int. J. Oncol. 2015, 46, 531–538. [Google Scholar] [CrossRef] [PubMed]
- Deng, Y.; Luan, F.; Zeng, L.; Zhang, Y.; Ma, K. MiR-429 suppresses the progression and metastasis of osteosarcoma by targeting ZEB1. EXCLI J. 2017, 16, 618–627. [Google Scholar] [CrossRef] [PubMed]
- Wang, Y.; Li, M.; Zang, W.; Ma, Y.; Wang, N.; Li, P.; Wang, T.; Zhao, G. MiR-429 up-regulation induces apoptosis and suppresses invasion by targeting Bcl-2 and SP-1 in esophageal carcinoma. Cell. Oncol. 2013, 36, 385–394. [Google Scholar] [CrossRef]
- Xue, H.; Tian, G.Y. MiR-429 regulates the metastasis and EMT of HCC cells through targeting RAB23. Arch. Biochem. Biophys. 2018, 637, 48–55. [Google Scholar] [CrossRef]
- Sung, H.; Ferlay, J.; Siegel, R.L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 2021, 71, 209–249. [Google Scholar] [CrossRef]
- Gu, B.; Shang, X.; Yan, M.; Li, X.; Wang, W.; Wang, Q.; Zhang, C. Variations in incidence and mortality rates of endometrial cancer at the global, regional, and national levels, 1990–2019. Gynecol. Oncol. 2021, 161, 573–580. [Google Scholar] [CrossRef]
- Kim, Y.; Kim, H.; Park, D.; Han, M.; Lee, H.; Lee, Y.S.; Choe, J.; Kim, Y.M.; Jeoung, D. miR-217 and CAGE form feedback loop and regulates the response to anti-cancer drugs through EGFR and HER2. Oncotarget 2016, 7, 10297–10321. [Google Scholar] [CrossRef]
- Kim, Y.; Park, D.; Kim, H.; Choi, M.; Lee, H.; Lee, Y.S.; Choe, J.; Kim, Y.M.; Jeoung, D. miR-200b and cancer/testis antigen CAGE form a feedback loop to regulate the invasion and tumorigenic and angiogenic responses of a cancer cell line to microtubule-targeting drugs. J. Biol. Chem. 2013, 288, 36502–36518. [Google Scholar] [CrossRef]
- Cho, B.; Lee, H.; Jeong, S.; Bang, Y.J.; Lee, H.J.; Hwang, K.S.; Kim, H.Y.; Lee, Y.S.; Kang, G.H.; Jeoung, D.I. Promoter hypomethylation of a novel cancer/testis antigen gene CAGE is correlated with its aberrant expression and is seen in premalignant stage of gastric carcinoma. Biochem. Biophys. Res. Commun. 2003, 307, 52–63. [Google Scholar] [CrossRef] [PubMed]
- Por, E.; Byun, H.J.; Lee, E.J.; Lim, J.H.; Jung, S.Y.; Park, I.; Kim, Y.M.; Jeoung, D.I.; Lee, H. The cancer/testis antigen CAGE with oncogenic potential stimulates cell proliferation by up-regulating cyclins D1 and E in an AP-1- and E2F-dependent manner. J. Biol. Chem. 2010, 285, 14475–14485. [Google Scholar] [CrossRef] [PubMed]
- Kim, Y.; Park, H.; Park, D.; Lee, Y.S.; Choe, J.; Hahn, J.H.; Lee, H.; Kim, Y.M.; Jeoung, D. Cancer/testis antigen CAGE exerts negative regulation on p53 expression through HDAC2 and confers resistance to anti-cancer drugs. J. Biol. Chem. 2010, 285, 25957–25968. [Google Scholar] [CrossRef]
- Kim, Y.; Yeon, M.; Jeoung, D. DDX53 Regulates Cancer Stem Cell-Like Properties by Binding to SOX-2. Mol. Cells 2017, 40, 322–330. [Google Scholar] [CrossRef] [PubMed]
- Vargas-Rondon, N.; Villegas, V.E.; Rondon-Lagos, M. The Role of Chromosomal Instability in Cancer and Therapeutic Responses. Cancers 2017, 10, 4. [Google Scholar] [CrossRef] [PubMed]
- Park, S.Y.; Kim, W.J.; Byun, J.H.; Lee, J.J.; Jeoung, D.; Park, S.T.; Kim, Y. Role of DDX53 in taxol-resistance of cervix cancer cells in vitro. Biochem. Biophys. Res. Commun. 2018, 506, 641–647. [Google Scholar] [CrossRef]
- Thiery, J.P. Epithelial-mesenchymal transitions in tumour progression. Nat. Rev. Cancer 2002, 2, 442–454. [Google Scholar] [CrossRef]
- Kwon, Y.; Kim, Y.; Jung, H.S.; Jeoung, D. Role of HDAC3-miRNA-CAGE Network in Anti-Cancer Drug-Resistance. Int. J. Mol. Sci. 2018, 20, 51. [Google Scholar] [CrossRef]
- Pasquinelli, A.E. MicroRNAs and their targets: Recognition, regulation and an emerging reciprocal relationship. Nat. Rev. Genet. 2012, 13, 271–282. [Google Scholar] [CrossRef]
- Korpal, M.; Kang, Y. The emerging role of miR-200 family of microRNAs in epithelial-mesenchymal transition and cancer metastasis. RNA Biol. 2008, 5, 115–119. [Google Scholar] [CrossRef]
- Qiu, M.; Liang, Z.; Chen, L.; Tan, G.; Wang, K.; Liu, L.; Liu, J.; Chen, H. MicroRNA-429 suppresses cell proliferation, epithelial-mesenchymal transition, and metastasis by direct targeting of BMI1 and E2F3 in renal cell carcinoma. Urol. Oncol. 2015, 33, 332.e339–332.e318. [Google Scholar] [CrossRef] [PubMed]
- Sheng, N.; Zhang, L.; Yang, S. MicroRNA-429 decreases the invasion ability of gastric cancer cell line BGC-823 by downregulating the expression of heparanase. Exp. Ther. Med. 2018, 15, 1927–1933. [Google Scholar] [CrossRef] [PubMed]
- Dong, H.; Hao, X.; Cui, B.; Guo, M. MiR-429 suppresses glioblastoma multiforme by targeting SOX2. Cell Biochem. Funct. 2017, 35, 260–268. [Google Scholar] [CrossRef] [PubMed]
- Lin, C.; Huang, F.; Li, Q.Z.; Zhang, Y.J. miR-101 suppresses tumor proliferation and migration, and induces apoptosis by targeting EZH2 in esophageal cancer cells. Int. J. Clin. Exp. Pathol. 2014, 7, 6543–6550. [Google Scholar]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Lee, K.-J.; Singh, N.; Bizuneh, M.; Kim, N.-H.; Kim, H.S.; Kim, Y.; Lee, J.-J.; Kim, J.H.; Kim, J.; Jeong, S.Y.; et al. miR-429 Suppresses Endometrial Cancer Progression and Drug Resistance via DDX53. J. Pers. Med. 2023, 13, 1302. https://doi.org/10.3390/jpm13091302
Lee K-J, Singh N, Bizuneh M, Kim N-H, Kim HS, Kim Y, Lee J-J, Kim JH, Kim J, Jeong SY, et al. miR-429 Suppresses Endometrial Cancer Progression and Drug Resistance via DDX53. Journal of Personalized Medicine. 2023; 13(9):1302. https://doi.org/10.3390/jpm13091302
Chicago/Turabian StyleLee, Kyung-Jun, Nitya Singh, Michael Bizuneh, Nam-Hyeok Kim, Hyeong Su Kim, Youngmi Kim, Jae-Jun Lee, Jung Han Kim, Jiye Kim, Soo Young Jeong, and et al. 2023. "miR-429 Suppresses Endometrial Cancer Progression and Drug Resistance via DDX53" Journal of Personalized Medicine 13, no. 9: 1302. https://doi.org/10.3390/jpm13091302